- Email: [email protected]
Correction to Lancet Oncol 2016; 17: 995, 1002
Corrections
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2014; 16: 767 2016; 17: 431, 434, 435 2016; 17: 953 Jeong S-Y, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014, 15: 767–74— In the Summary of this Article, the registered trial number was incorrect, and should have read NCT00470951. This correction has been made to the online version as of June 28, 2016.
Correction to Lancet Oncol 2015; 16: 1479 Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16: 1473–82—In table 3 of this Article, the number of patients in the lenvatinib plus everolimus group with Grade 3 constipation should be 0. This correction has been made to the online version as of June 28, 2016.
Correction to Lancet Oncol 2016; 17: 351 Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto— GBG 69): a randomised, phase 3 trial. Lancet Oncol 2016; 17: 345–56—In this Article, the data in the second sentence of the third paragraph of the Results section should have read “In multivariable logistic regression analysis, nab-paclitaxel remained an independent predictor for achievement of pathological complete response after adjustment for baseline and minimisation factors (OR 1·59; 95% CI 1·20–2·11; p=0·0013)”. The corresponding data in the appendix have also been updated. These corrections have been made to the online version as of June 28, 2016. www.thelancet.com/oncology Vol 17 July 2016
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, doubleblind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425–39— In figures 2A, 5A, 5B, and 5C, the Kaplan-Meier curves should have intersected with the y-axis at the 100% mark. Furthermore, in figure 4, the hazard ratios (HRs) should have been labelled as “supremum HR” rather than “subpremium HR”. These corrections have been made to the online version as of June 28, 2016.
Correction to Lancet Oncol 2016; 17: 888, 890, 892 Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17: 883–95—In this Article, the first line in the third paragraph of the Results, “blinded independent central review” should have been “investigator-assessed RECIST”. In the seventh paragraph of the Results, the number of patients in the nivolumab 3 mg/kg plus ipilimumab 1 mg/kg cohort who had diarrhoea as a serious adverse event should have been two (4%), not four (7%). In the seventh paragraph of the Results, “one patient with hypothyroidism, hyperglycaemia and increased alanine aminotransferase” should have been “one patient with hypothyroidism and hyperglycaemia”. These corrections have been made to the online version as of June 28, 2016, and the printed version is correct.
Weber JS, Geoff Gibney, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943–55—In figure 5, under the headings “Nivolumab followed by ipilimumab” and “Ipilimumab followed by nivolumab”, the text should have read “Number of events/ number of patients”. This correction has been made to the online version as of June 28, 2016, and the printed version is correct.
Correction to Lancet Oncol 2016; 17: 995, 1002 Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial Lancet Oncol 2016; 17: 994–1003—In this Article, the order of references 7–11 has been corrected and the fourth sentence of the second paragraph of the introduction has been corrected to read “Furthermore, an analysis of HRQoL scores according to the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) questionnaire (a subscale of the 15-item FKSI-15) showed that median change from baseline increased over time with nivolumab treatment.” These corrections have been made to the online version as of June 28, 2016, and the printed version is correct.
e270
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2014; 16: 767 2016; 17: 431, 434, 435 2016; 17: 953 Jeong S-Y, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014, 15: 767–74— In the Summary of this Article, the registered trial number was incorrect, and should have read NCT00470951. This correction has been made to the online version as of June 28, 2016.
Correction to Lancet Oncol 2015; 16: 1479 Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16: 1473–82—In table 3 of this Article, the number of patients in the lenvatinib plus everolimus group with Grade 3 constipation should be 0. This correction has been made to the online version as of June 28, 2016.
Correction to Lancet Oncol 2016; 17: 351 Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto— GBG 69): a randomised, phase 3 trial. Lancet Oncol 2016; 17: 345–56—In this Article, the data in the second sentence of the third paragraph of the Results section should have read “In multivariable logistic regression analysis, nab-paclitaxel remained an independent predictor for achievement of pathological complete response after adjustment for baseline and minimisation factors (OR 1·59; 95% CI 1·20–2·11; p=0·0013)”. The corresponding data in the appendix have also been updated. These corrections have been made to the online version as of June 28, 2016. www.thelancet.com/oncology Vol 17 July 2016
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, doubleblind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425–39— In figures 2A, 5A, 5B, and 5C, the Kaplan-Meier curves should have intersected with the y-axis at the 100% mark. Furthermore, in figure 4, the hazard ratios (HRs) should have been labelled as “supremum HR” rather than “subpremium HR”. These corrections have been made to the online version as of June 28, 2016.
Correction to Lancet Oncol 2016; 17: 888, 890, 892 Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17: 883–95—In this Article, the first line in the third paragraph of the Results, “blinded independent central review” should have been “investigator-assessed RECIST”. In the seventh paragraph of the Results, the number of patients in the nivolumab 3 mg/kg plus ipilimumab 1 mg/kg cohort who had diarrhoea as a serious adverse event should have been two (4%), not four (7%). In the seventh paragraph of the Results, “one patient with hypothyroidism, hyperglycaemia and increased alanine aminotransferase” should have been “one patient with hypothyroidism and hyperglycaemia”. These corrections have been made to the online version as of June 28, 2016, and the printed version is correct.
Weber JS, Geoff Gibney, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943–55—In figure 5, under the headings “Nivolumab followed by ipilimumab” and “Ipilimumab followed by nivolumab”, the text should have read “Number of events/ number of patients”. This correction has been made to the online version as of June 28, 2016, and the printed version is correct.
Correction to Lancet Oncol 2016; 17: 995, 1002 Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial Lancet Oncol 2016; 17: 994–1003—In this Article, the order of references 7–11 has been corrected and the fourth sentence of the second paragraph of the introduction has been corrected to read “Furthermore, an analysis of HRQoL scores according to the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) questionnaire (a subscale of the 15-item FKSI-15) showed that median change from baseline increased over time with nivolumab treatment.” These corrections have been made to the online version as of June 28, 2016, and the printed version is correct.
e270